Glaukos Corporation

WHO'M
ai
Digital Profiler. Simply click the AI button
CUSIP
377322102
SEDOL
BYMWL19
CIK
0001192448
www.glaukos.com
LEI:
©
FIGI: BBG000WG2LQ1
GKOS
Glaukos Corporation
GICS: - · Sector: Healthcare · Sub-Sector: Medical Devices
NAME
Glaukos Corporation
ISIN
US3773221029
TICKER
GKOS
MIC
XNYS
REUTERS
GKOS.N
BLOOMBERG
GKOS US
BUILD THEMEFOLIO SHARE IDEAS DISCUSS
LEVERAGE INVEST
EN 728x90
Financial Intelligence
360° iHub Crowd iFeed ATH Tracker Index Tracker ETF TF Spicy2 X-Billboard
FOR INVESTORS
FOR TRADERS
Securities Trading Warrants
TradingView ActivTrader MT4 MT5
The X-News Explorer is the ultimate source of information for investors with an affinity for the stock market who want to get a quick and convenient overview of the current news situation of a listed company. Various newswire services are available to you here. If a news alert is displayed, you will find company news that may be of interest to you. This service is provided by BusinessWire.
Wed, 16.10.2024       Glaukos
US3773221029

Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced that the second Phase 3 confirmatory pivotal trial for Epioxa™ (Epi-on), its next-generation corneal cross-linking iLink therapy for the trea...
Read More
Glaukos
Technical Analysis Termsheet Terminal
Permalink
Mon, 14.10.2024       Glaukos
US3773221029

Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, announced today that its technologies will be featured in various scientific programming at the American Academy of Ophthalmology (AAO) annual meeting, being...
Read More
Glaukos
Technical Analysis Termsheet Terminal
Permalink
Wed, 09.10.2024       Glaukos
US3773221029

Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, plans to release third quarter 2024 financial results after the market close on Monday, November 4, 2024. The company’s management will discuss the results d...
Read More
Glaukos
Technical Analysis Termsheet Terminal
Permalink
Fri, 16.08.2024       Glaukos
US3773221029

Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced that its management is scheduled to participate in the following upcoming investor conferences: Wells Fargo Healthcare Conference on Wedne...
Read More
Glaukos
Technical Analysis Termsheet Terminal
Permalink
We are different
OPEN FINANCIAL
DATA & KNOWLEDGE HUB
We make the difference
Information on product placements